Abstract
Glycoprotein IIb/IIIa inhibitors and low molecular heparins are important new components of the medical treatment for acute coronary syndromes (ACS). Renal insufficiency is a common comorbid condition and high-risk marker for ACS. The safety and efficacy of these treatments in ACS are dependent on the pharmacokinetics of the specific medication. Even though these treatments have been studied in large randomized controlled trials in ACS, there are few prospective data regarding their safety or efficacy in renal insufficiency. Most have been shown to be safe and effective in mild to moderate degrees of renal insufficiency; none have been thoroughly studied in severe renal disease or in patients requiring dialysis therapy. Future prospective trials should include patients with more severe renal insufficiency, as well as combinations of the current recommended therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
